Researchers from the University of Warsaw, as part of a consortium of Polish scientific institutions, will develop mRNA technology with high efficiency and application in anti-cancer therapies. The project was co-financed in the amount of almost 70 million zloty under the Virtual Research Institute program.
The research project “Horizon of excellence in applications of matrix RNA in immuno-oncology [HERO]” will be carried out by a consortium of four Polish research units: International Institute of Molecular and Cell Biology in Warsaw (research team leader unit), University of Warsaw, Institute of Physical Chemistry of the Polish Academy of Sciences and Warsaw Medical University.
The research team will work towards the development of highly effective therapeutic mRNA technology and its application in cancer immunotherapy. It is composed of: prof. Andrzej Dziembowski – leader (MIBMiK), prof. Jacek Jemielity (CeNT UW), dr hab. Joanna Kowalska (Faculty of Physics, University of Warsaw), prof. Dominika Nowis (MUW), prof. Marta Miączyńska (MIBMiK), prof. Jakub Gołąb (Medical University of Warsaw), prof. Robert Hołyst (IPC PAS) and prof. Marcin Nowotny (MIBMiK).
The authors of the HERO project were awarded nearly PLN 70 million for its implementation in the completed first competition of the Virtual Research Institute (WIB) program. The WIB funds research in the field of medical biotechnology – oncology. The international panel of competition experts appreciated the scientific value of the project and its high commercialization potential.
More information can be found at: https://www.uw.edu.pl/70-mln-zl-na-opracowanie-technologii-mrna-przeciw-nowotworom/